NEWRON PHARMACEUT. EO-20 (NP5) — Financial Flexibility Index
NEWRON PHARMACEUT. EO-20 (NP5) has a Financial Flexibility Index of -0.03x as of December 2025. Free cash flow of €-1.31 Million (operating CF €-1.33 Million minus capex €15.73K) represents 0% of total liabilities (€51.15 Million). Check NP5 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NEWRON PHARMACEUT. EO-20 Financial Flexibility Index (2005–2025)
Historical Financial Flexibility Index trend for NEWRON PHARMACEUT. EO-20 across 21 annual periods. See NEWRON PHARMACEUT. EO-20 short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for NEWRON PHARMACEUT. EO-20 (2005–2025)
Year-by-year free cash flow to debt coverage for NEWRON PHARMACEUT. EO-20. For the full company profile including market capitalisation, see NEWRON PHARMACEUT. EO-20 market capitalisation.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.64x | €32.61 Million | €32.56 Million | €51.15 Million | ▲ +326.2% |
| 2024 | -0.28x | €-17.60 Million | €-17.61 Million | €62.45 Million | ▼ -55.2% |
| 2023 | -0.18x | €-10.13 Million | €-10.14 Million | €55.77 Million | ▲ +16.0% |
| 2022 | -0.22x | €-11.07 Million | €-11.09 Million | €51.23 Million | ▲ +10.3% |
| 2021 | -0.24x | €-11.43 Million | €-11.45 Million | €47.38 Million | ▲ +47.4% |
| 2020 | -0.46x | €-15.55 Million | €-15.59 Million | €33.95 Million | ▲ +50.9% |
| 2019 | -0.93x | €-21.93 Million | €-21.98 Million | €23.49 Million | ▲ +69.7% |
| 2018 | -3.08x | €-15.92 Million | €-15.95 Million | €5.16 Million | ▼ -95.1% |
| 2017 | -1.58x | €-8.38 Million | €-8.40 Million | €5.30 Million | ▲ +44.6% |
| 2016 | -2.85x | €-19.51 Million | €-19.58 Million | €6.84 Million | ▼ -61.9% |
| 2015 | -1.76x | €-12.80 Million | €-12.86 Million | €7.27 Million | ▼ -37.9% |
| 2014 | -1.28x | €-9.98 Million | €-10.00 Million | €7.81 Million | ▼ -26.8% |
| 2013 | -1.01x | €-10.61 Million | €-10.69 Million | €10.53 Million | ▼ -394.2% |
| 2012 | 0.34x | €5.84 Million | €5.83 Million | €17.04 Million | ▲ +148.4% |
| 2011 | -0.71x | €-4.94 Million | €-4.94 Million | €6.98 Million | ▲ +74.3% |
| 2010 | -2.75x | €-19.12 Million | €-19.13 Million | €6.94 Million | ▼ -48.5% |
| 2009 | -1.85x | €-22.99 Million | €-23.06 Million | €12.39 Million | ▼ -39.6% |
| 2008 | -1.33x | €-19.57 Million | €-19.93 Million | €14.73 Million | ▼ -27.4% |
| 2007 | -1.04x | €-13.53 Million | €-13.87 Million | €12.97 Million | ▼ -99.3% |
| 2006 | -0.52x | €-9.58 Million | €-9.63 Million | €18.30 Million | ▲ +76.2% |
| 2005 | -2.20x | €-14.23 Million | €-14.33 Million | €6.48 Million | — |